Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Clinical tool

Localised Prostate Cancer Risk Group Calculator

Low, favourable and unfavourable intermediate, high and locally advanced

Updated: 27 October 20261 min read3 references

Risk group of localised prostate cancer (EAU; based on D'Amico) with intermediate risk split into favourable and unfavourable.

ISUP grade group (Gleason)
Clinical T stage

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Group definitions

EAU risk groups (based on D’Amico) [1, 2]
GroupDefinition
LowPSA below 10 and ISUP 1 and cT1–cT2a
IntermediatePSA 10–20 or ISUP 2–3 or cT2b
HighPSA above 20 or ISUP 4–5 or cT2c
Locally advancedcT3–cT4 or cN1 (any PSA and ISUP)

Favourable and unfavourable intermediate: intermediate risk is unfavourable with ISUP 3 (Gleason 4+3), 50% or more positive cores, or more than one intermediate risk factor [3]. The split guides adding short-term hormone therapy to radiotherapy.

Read more: prostate cancer.

Related cancer types

Prostate cancer

Treatment regimens (physicians)

Docetaxel in metastatic prostate cancerDarolutamide with docetaxel and hormone therapy (ARASENS)

Physician tools and lessons

10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?

References

3 references
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerD'Amico AV, Whittington R, Malkowicz SB, et al · JAMA · 1998;280:969-74
    DOIPubMed Back to text
  2. 2
    EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentMottet N, van den Bergh RCN, Briers E, et al · Eur Urol · 2021;79:243-262
    DOIPubMed Back to text
  3. 3
    A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapyZumsteg ZS, Spratt DE, Pei I, et al · Eur Urol · 2013;64:895-902
    DOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/prostate-cancer-risk-group/

Related pages

27 October 2026 Should I Be Screened for Lung Cancer? (Pack-Year Calculator) Pack-year calculator and lung cancer screening eligibility for low-dose CT according to the US Preventive Services Task Force (2021). 27 October 2026 Child-Pugh and ALBI Score Calculator in Liver Cancer Child-Pugh score and ALBI grade calculator to assess liver function in hepatocellular carcinoma (HCC) and choose treatment according to BCLC. 27 October 2026 Colon Cancer TNM Staging Calculator (AJCC 8th Edition) Colorectal cancer staging calculator using the AJCC 8th edition TNM system, with the adjuvant chemotherapy recommendation for each stage.